If you have been reading about incretin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
The script was co-written by Paul Dehn, who had worked in the Special Operations Executive as an assassin during World War II. The film closely follows the plot of the original source text. One exception is that the name of the principal female character in the novel, Liz Gold, is changed to Nan Perry in the film, reputedly because Martin Ritt was worried about the potential confusion in the media with Burton's wife, Elizabeth Taylor. Le Carré's preferred choice was Rita Tushingham, he initially felt Bloom was "too beautiful, classy," but later changed his mind, feeling she provided a proper foil to Burton. Le Carré favoured Trevor Howard or Peter Finch for the role of Leamas, but they were rejected for not being enough of a box office draw; Burt Lancaster was also considered but was rejected for not being able to put on a convincing British accent. Richard Burton, the eventual choice of the producers, butted heads with director Martin Ritt during the course of the production. The atmosphere on set was also tense from both the presence of Burton's wife, Elizabeth Taylor, as well as the romantic history between co-stars Burton and Bloom. Burton had initially demanded Taylor play Perry, but Martin Ritt insisted on Bloom. Several of the key cast and crew were expatriate Americans who had been blacklisted, including director Martin Ritt, actor Sam Wanamaker and composer Sol Kaplan. Some of the cast and crew had previously worked on the James Bond films, including screenwriter Paul Dehn (who wrote Goldfinger) and actor Bernard Lee (the original M).
=== In the field === The study of birds in the field was helped enormously by improvements in optics. Photography made it possible to document birds in the field with great accuracy. High-power spotting scopes today allow observers to detect minute morphological differences that were earlier possible only by examination of the specimen "in the hand".
Delayed macrophage recruitment was observed in B-cell deficient mice lacking serum antibodies. These signaling molecules together cause an influx of macrophages, which peaks during the third week after injury. While Schwann cells mediate the initial stage of myelin debris clean up, macrophages come in to finish the job. Macrophages are facilitated by opsonins, which label debris for removal. The 3 major groups found in serum include complement, pentraxins, and antibodies. However, only complement has shown to help in myelin debris phagocytosis. Murinson et al. (2005) observed that non-myelinated or myelinated Schwann cells in contact with an injured axon enter cell cycle thus leading to proliferation. Observed time duration for Schwann cell divisions were approximately 3 days after injury. Possible sources of proliferation signal are attributed to the ErbB2 receptors and the ErbB3 receptors. This proliferation could further enhance the myelin cleaning rates and plays an essential role in regeneration of axons observed in PNS. Schwann cells emit growth factors that attract new axonal sprouts growing from the proximal stump after complete degeneration of the injured distal stump. This leads to possible reinnervation of the target cell or organ. However, the reinnervation is not necessarily perfect, as possible misleading occurs during reinnervation of the proximal axons to target cells.
In other words, the lack of positive support and validation increases the risk for divorce. Because of the expansive research done on the significance of social support within a marriage, it is important to understand that this research was inspired by a theory called the attachment theory perspective. Attachment theory stresses the importance of support and care giving in a relationship for the development of trust and security. Attachment theory, as conceptualized by Collins and Feeney (2000) is an interpersonal, transactional process that involves one partners caregiving responses.
== Two step non-laser == In two-step non-laser methods, the material removal from the sample and the ionization steps are separate. Probe electrospray ionization (PESI) is a modified version of conventional electrospray ionization in which the capillary for sample solution transferring is replaced by a solid needle with a sharp tip. Compared with conventional electrospray ionization, high salt tolerance, direct sampling, and low sample consumption are found with PESI. PESI is not a continuous process; the needle for sampling and spraying is driven up and down at a frequency of 3–5 Hz.
Sources: en.wikipedia.org
Wolpaw and Pinkerton turned down invitations to return to Valve early in the Alyx development. Instead, Valve recruited Rob Yescombe of The Invisible Hours, who worked on Alyx in 2017 and 2018. Yescombe's narrative was darker than previous Half-Life games, with scenes of dread, torture and horror. The antagonist was a female Combine officer named Hahn; in one proposed ending, Alyx would kill Hahn in revenge for torturing her father. Yescombe also proposed an ending in which Alyx and the G-Man would travel back in time to the events of the first Half-Life to prevent Freeman from triggering the alien invasion. After the company-wide playtest in 2018, feedback was overwhelmingly positive save for the story, which employees scored the lowest of any Valve game. Morasky described it as "dark, serious and laborious", likening it to a Zack Snyder superhero film. The designer Corey Peters said the feedback vindicated their misgivings. Valve initially planned to launch Alyx alongside its Index VR headset in June 2019, but delayed it to address the story. They re-enlisted Wolpaw and Pinkerton to rewrite the plot and dialogue while preserving the gameplay, along with Jake Rodkin and Sean Vanaman, who had joined when Valve acquired Campo Santo. Laidlaw, who retired in 2016, denied reports that he had provided consultation, saying he had confidence in Pinkerton and Wolpaw and that he did not want them "second-guessing" him. The new writing team identified three problems. First, the nature of a prequel meant that players knew the characters would survive, reducing suspense.
Valproate is a weak or low-potency histone deacetylase inhibitor, specifically of the class I HDAC1, HDAC2, HDAC3, and HDAC8, but not of other HDACs. Earlier studies found a wide range of inhibitory potencies of valproate against HDACs, ranging from low micromolar to millimolar concentrations, but subsequent work with improved methodology has supported greater inhibitory potencies, with IC50Tooltip half-maximal inhibitory concentration values in the range of 36 to 219 μM for the class I HDACs. For comparison, valproate was found to be 4- to 46-fold less potent in inhibiting the class I HDACs relative to butyric acid (butyrate). By inhibiting HDACs, valproate promotes more transcriptionally active chromatin structures, that is it exerts an epigenetic effect. This has been proven in mice: Valproic acid induced histone hyperacetylation had brain function effects on the next generation of mice through changes in sperm DNA methylation. Intermediate molecules include VEGF, BDNF, and GDNF.
Many species have so-called sex chromosomes that determine the sex of each organism. In humans and many other animals, the Y chromosome contains the gene that triggers the development of the specifically male characteristics. In evolution, this chromosome has lost most of its content and also most of its genes, while the X chromosome is similar to the other chromosomes and contains many genes. This being said, Mary Frances Lyon discovered that there is X-chromosome inactivation during reproduction to avoid passing on twice as many genes to the offspring. Lyon's discovery led to the discovery of X-linked diseases.
When the text was disclosed in the British press, it generated a storm of anti-German feeling. In the baggage of the raiding column, to the embarrassment of Britain, the Boers found telegrams from Rhodes and other plotters in Johannesburg. Chamberlain had approved Rhodes' plans to send armed assistance in the case of a Johannesburg uprising, but he quickly moved to condemn the raid. Rhodes was censured at the Cape and London parliamentary inquiries, and forced to resign as Prime Minister and Chairman of the British South Africa Company. The Boer government handed their prisoners over to the British for trial. Jameson was tried in England, where the press and London society, inflamed by anti-Boer and anti-German feeling and in a frenzy of jingoism, treated him as a hero. Although sentenced to 15 months imprisonment, Jameson was rewarded by being named Prime Minister of the Cape Colony (1904–08) and ultimately anointed as one of the founders of the Union of South Africa. For conspiring with Jameson, the uitlander members of the Reform Committee (Transvaal) were tried in the Transvaal courts and found guilty of treason. The four leaders were sentenced to death, but this was commuted to 15 years' imprisonment. In 1896, the other members of the committee were released on payment of £2,000 in fines, all paid by Rhodes. One Reform Committee member, Frederick Gray, committed suicide while in Pretoria jail. His death was a factor in softening the Transvaal government's attitude to the surviving prisoners. Jan C. Smuts wrote, in 1906:
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.